// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Citrullinated glucose-regulated protein 78 is a novel candidate target for cancer immunotherapy

Victoria Brentville - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Interferon Gamma

Targeting complement factor H mediated tumor immune and complement evasion as a next generation approach

Matthew Kraman - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Inhibition of acid sensing by GPR65 normalises gene expression in macrophages, increases immune cell infiltration in tumors, and restrains subcutaneous MC38 growth in mice

Alastair Corbin - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses and synergises with immune checkpoint blockade

Yaara Ofir -Rosenfeld - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Gynaecological cancer

N/A

A novel class of T cell-activating antibody that selectively targets the TCR b chain to promote antitumor activity through activation and expansion of a novel, polyclonal effector memory T cell subset

Andy Bayliffe - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterising the immunotherapeutic capabilities of bacterial outer-membrane vesicles

Jack Firth - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Utility of humanized animal models for in vivo evaluation of NK TICA™ novel Bicycle® tumor targeted immune cell agonists® Bicycle TICA™ designed to engage NK cells

Lukas Stanczuk - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A CRISPR-Cas9 screen identifies novel epigenetic regulators of T cell exhaustion

Gayathri Bommakanti - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon Gamma

An holistic and intergrated approach for investigating the bacterial microbiome, gene expression profile and immune cell profile in the non-muscle invasive bladder cancer tumour microenvironment

Tyler Wooldridge - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Targeting sialic acid on stromal cells reverses T cell suppression in the colorectal tumour microenvironment a new tumour stromal cell immune checkpoint

Aideen Ryan - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

NPC-09

Interplay between the tumour and gut microbiome and the tumour immune microenvironment in complete responder cancer patients

Nicola Annels - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Assessing the correlation between CD8 cell PET Imaging with 89-Zr-Crefmirlimab Berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy

Michael Postow - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)

Wade Iams - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

EDP 202

Reduced Rate of Brain Atrophy after 5 Years of Ocrelizumab Treatment in Patients with Ppms from the Phase III Oratorio Trial

Gavin Giovannoni - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Ocrelizumab

The Occurrence of Infusion-Related Reactions Among Patients with Multiple Sclerosis Undergoing Treatment with Ocrevus (Ocrelizumab) in a Community Setting Receiving a Standard Pre-Infusion Protocol.

Hollis O'Nell-Meyer - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Ocrelizumab

Clarity Extension: Long-Term Efficacy of Cladribine Tablets in Patients with High Disease Activity at Baseline Following Switch to Placebo

Patrick Vermersch - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Cladribine

Feasibility of Classic MS Assessing Long-Term Efficacy for Patients with Multiple Sclerosis Treated with Cladribine Tablets in the Phase 3 Trials

Mark S Freedman - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Cladribine

Efficacy of Cladribine Tablets 3.5mg/Kg in Patients with Relapsing Multiple Sclerosis Aged Above and below 45 Years; Clarity and Clarity Extension

Gavin Giovannoni - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Cladribine

Severity and Frequency of Relapses in Patients with Relapsing-Remitting MS Treated with Cladribine Tablets in Clarity and Placebo in Clarity Extension

Sven Schippling - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Cladribine

Relapse Outcomes in Clarity EXT Patients Treated with Cladribine Tablets or Placebo Were Comparable Regardless of the between-Trial Bridging Intervals

Kottil Rammohan - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Cladribine

Copyright © 2026. QuantiNova All rights reserved